Striatal monoamine terminals in Lewy body dementia and Alzheimer's disease

Sid Gilman, Robert A. Koeppe, Roderick Little, Hyonggin An, Larry Junck, Bruno Giordani, Carol Persad, Mary Heumann, Kris Wernette

Research output: Contribution to journalArticle

49 Citations (Scopus)

Abstract

We used positron emission tomography (PET) with (+)-[11C] dihydrotetrabenazine ([+]-[11C]DTBZ) to examine striatal monoaminergic presynaptic terminal density in 20 patients with dementia with Lewy bodies (DLB), 25 with Alzheimer's disease (AD), and 19 normal elderly controls. Six DLB patients developed parkinsonism at least 1 year before dementia (DLB/PD) and 14 developed dementia before parkinsonism or at about the same time (DLB/AD). Striatal mean binding potential was decreased by 62 to 77% in the DLB/PD group and 45 to 67% in the DLB/AD compared to AD and control. Binding was lower in the DLB/PD group than the DLB/AD, but the differences reached only marginal significance in the caudate nucleus. No differences were found between AD and control groups though a few AD patients had binding values below the range of the controls. Subsequent neuropathological examination in one AD patient revealed both AD and DLB changes despite the absence of clinical parkinsonism. Both DLB groups had an anterior to posterior binding deficit gradient relative to controls, largest in posterior putamen, smaller in anterior putamen, smallest in caudate nucleus. The DLB/AD group showed significant binding asymmetry only in posterior putamen. We conclude that PET with (+)-[11C]DTBZ differentiates DLB from AD, and decreased binding in AD may indicate subclinical DLB pathology in addition to AD pathology.

Original languageEnglish
Pages (from-to)774-780
Number of pages7
JournalAnnals of Neurology
Volume55
Issue number6
DOIs
Publication statusPublished - 2004 Jun 1
Externally publishedYes

Fingerprint

Corpus Striatum
Lewy Body Disease
Alzheimer Disease
Dementia
Putamen
Parkinsonian Disorders
Caudate Nucleus
Positron-Emission Tomography
Pathology
Lewy Bodies
Presynaptic Terminals

ASJC Scopus subject areas

  • Neuroscience(all)

Cite this

Gilman, S., Koeppe, R. A., Little, R., An, H., Junck, L., Giordani, B., ... Wernette, K. (2004). Striatal monoamine terminals in Lewy body dementia and Alzheimer's disease. Annals of Neurology, 55(6), 774-780. https://doi.org/10.1002/ana.20088

Striatal monoamine terminals in Lewy body dementia and Alzheimer's disease. / Gilman, Sid; Koeppe, Robert A.; Little, Roderick; An, Hyonggin; Junck, Larry; Giordani, Bruno; Persad, Carol; Heumann, Mary; Wernette, Kris.

In: Annals of Neurology, Vol. 55, No. 6, 01.06.2004, p. 774-780.

Research output: Contribution to journalArticle

Gilman, S, Koeppe, RA, Little, R, An, H, Junck, L, Giordani, B, Persad, C, Heumann, M & Wernette, K 2004, 'Striatal monoamine terminals in Lewy body dementia and Alzheimer's disease', Annals of Neurology, vol. 55, no. 6, pp. 774-780. https://doi.org/10.1002/ana.20088
Gilman S, Koeppe RA, Little R, An H, Junck L, Giordani B et al. Striatal monoamine terminals in Lewy body dementia and Alzheimer's disease. Annals of Neurology. 2004 Jun 1;55(6):774-780. https://doi.org/10.1002/ana.20088
Gilman, Sid ; Koeppe, Robert A. ; Little, Roderick ; An, Hyonggin ; Junck, Larry ; Giordani, Bruno ; Persad, Carol ; Heumann, Mary ; Wernette, Kris. / Striatal monoamine terminals in Lewy body dementia and Alzheimer's disease. In: Annals of Neurology. 2004 ; Vol. 55, No. 6. pp. 774-780.
@article{d9164218d906436b8b9a97654b57d343,
title = "Striatal monoamine terminals in Lewy body dementia and Alzheimer's disease",
abstract = "We used positron emission tomography (PET) with (+)-[11C] dihydrotetrabenazine ([+]-[11C]DTBZ) to examine striatal monoaminergic presynaptic terminal density in 20 patients with dementia with Lewy bodies (DLB), 25 with Alzheimer's disease (AD), and 19 normal elderly controls. Six DLB patients developed parkinsonism at least 1 year before dementia (DLB/PD) and 14 developed dementia before parkinsonism or at about the same time (DLB/AD). Striatal mean binding potential was decreased by 62 to 77{\%} in the DLB/PD group and 45 to 67{\%} in the DLB/AD compared to AD and control. Binding was lower in the DLB/PD group than the DLB/AD, but the differences reached only marginal significance in the caudate nucleus. No differences were found between AD and control groups though a few AD patients had binding values below the range of the controls. Subsequent neuropathological examination in one AD patient revealed both AD and DLB changes despite the absence of clinical parkinsonism. Both DLB groups had an anterior to posterior binding deficit gradient relative to controls, largest in posterior putamen, smaller in anterior putamen, smallest in caudate nucleus. The DLB/AD group showed significant binding asymmetry only in posterior putamen. We conclude that PET with (+)-[11C]DTBZ differentiates DLB from AD, and decreased binding in AD may indicate subclinical DLB pathology in addition to AD pathology.",
author = "Sid Gilman and Koeppe, {Robert A.} and Roderick Little and Hyonggin An and Larry Junck and Bruno Giordani and Carol Persad and Mary Heumann and Kris Wernette",
year = "2004",
month = "6",
day = "1",
doi = "10.1002/ana.20088",
language = "English",
volume = "55",
pages = "774--780",
journal = "Annals of Neurology",
issn = "0364-5134",
publisher = "John Wiley and Sons Inc.",
number = "6",

}

TY - JOUR

T1 - Striatal monoamine terminals in Lewy body dementia and Alzheimer's disease

AU - Gilman, Sid

AU - Koeppe, Robert A.

AU - Little, Roderick

AU - An, Hyonggin

AU - Junck, Larry

AU - Giordani, Bruno

AU - Persad, Carol

AU - Heumann, Mary

AU - Wernette, Kris

PY - 2004/6/1

Y1 - 2004/6/1

N2 - We used positron emission tomography (PET) with (+)-[11C] dihydrotetrabenazine ([+]-[11C]DTBZ) to examine striatal monoaminergic presynaptic terminal density in 20 patients with dementia with Lewy bodies (DLB), 25 with Alzheimer's disease (AD), and 19 normal elderly controls. Six DLB patients developed parkinsonism at least 1 year before dementia (DLB/PD) and 14 developed dementia before parkinsonism or at about the same time (DLB/AD). Striatal mean binding potential was decreased by 62 to 77% in the DLB/PD group and 45 to 67% in the DLB/AD compared to AD and control. Binding was lower in the DLB/PD group than the DLB/AD, but the differences reached only marginal significance in the caudate nucleus. No differences were found between AD and control groups though a few AD patients had binding values below the range of the controls. Subsequent neuropathological examination in one AD patient revealed both AD and DLB changes despite the absence of clinical parkinsonism. Both DLB groups had an anterior to posterior binding deficit gradient relative to controls, largest in posterior putamen, smaller in anterior putamen, smallest in caudate nucleus. The DLB/AD group showed significant binding asymmetry only in posterior putamen. We conclude that PET with (+)-[11C]DTBZ differentiates DLB from AD, and decreased binding in AD may indicate subclinical DLB pathology in addition to AD pathology.

AB - We used positron emission tomography (PET) with (+)-[11C] dihydrotetrabenazine ([+]-[11C]DTBZ) to examine striatal monoaminergic presynaptic terminal density in 20 patients with dementia with Lewy bodies (DLB), 25 with Alzheimer's disease (AD), and 19 normal elderly controls. Six DLB patients developed parkinsonism at least 1 year before dementia (DLB/PD) and 14 developed dementia before parkinsonism or at about the same time (DLB/AD). Striatal mean binding potential was decreased by 62 to 77% in the DLB/PD group and 45 to 67% in the DLB/AD compared to AD and control. Binding was lower in the DLB/PD group than the DLB/AD, but the differences reached only marginal significance in the caudate nucleus. No differences were found between AD and control groups though a few AD patients had binding values below the range of the controls. Subsequent neuropathological examination in one AD patient revealed both AD and DLB changes despite the absence of clinical parkinsonism. Both DLB groups had an anterior to posterior binding deficit gradient relative to controls, largest in posterior putamen, smaller in anterior putamen, smallest in caudate nucleus. The DLB/AD group showed significant binding asymmetry only in posterior putamen. We conclude that PET with (+)-[11C]DTBZ differentiates DLB from AD, and decreased binding in AD may indicate subclinical DLB pathology in addition to AD pathology.

UR - http://www.scopus.com/inward/record.url?scp=2542580254&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=2542580254&partnerID=8YFLogxK

U2 - 10.1002/ana.20088

DO - 10.1002/ana.20088

M3 - Article

VL - 55

SP - 774

EP - 780

JO - Annals of Neurology

JF - Annals of Neurology

SN - 0364-5134

IS - 6

ER -